Press & News

ViewReleaseInStandardHtml

Bulletin from Annual General Meeting in Boule Diagnostics AB on May 11, 2017

The Annual General Meeting (the ”AGM”) decided to adopt the balance sheet and income statement, consolidated income and balance sheet for 2016. Furthermore, it was decided that a dividend of SEK 1.40 per share will be distributed and remaining result shall be carried forward.

The AGM also decided to discharge the board members and the CEO from liability for 2016.

The AGM approved the nominating committee’s proposal that the board shall consist of four board members without deputies.

The AGM decided that the remuneration to the chairman of the board shall amount to SEK 400,000 (350,000 for 2016) and that the remuneration to the other board members shall be SEK 200,000 (175,000 for 2016) each. The entirety of the board is expected to fulfill the duties of the audit and remuneration committees, and no additional remuneration is proposed for committee work. The total remuneration to the board is hence amounted to SEK 1,000,000 (875,000 for 2016).

The AGM also decided that the remuneration to the auditor, as previous, will be on current account.

The AGM decided through re-election that the board will consist of the members Peter Ehrenheim, Thomas Eklund, Karin Dahllöf and Jon Risfelt until the end of the next Annual General Meeting. Peter Ehrenheim was re-elected chairman of the board.

Öhrlings PriceWaterhouseCoopers AB was re-elected as the company’s auditor, with Leonard Daun as auditor in charge, until the end of the Annual General Meeting of 2018.

The AGM approved the proposed instructions for the nomination committee.

The AGM approved the board’s proposed remuneration guidelines for senior management.

The AGM approved the board’s proposal to be authorized to increase share capital through the issue of new shares, options and/or convertibles.                                                                                                     

The AGM approved the board’s proposal to be authorized to make decisions on the acquisition and/or transferal of own shares.

The AGM approved the board’s proposal for the incentive program 2017/2020.

Complete proposals regarding the AGM’s decisions are available on Boule’s website, www.boule.se.

For further information, please contact:

Peter Ehrenheim, chairman of the board Boule Diagnostics AB, phone 0706-67 57 11

Fredrik Dalborg, CEO and Group President Boule Diagnostics AB, phone 070-558 51 05

About Boule Diagnostics AB (publ)

Boule Diagnostics AB (publ) is one of the few companies on the global diagnostics market that develops, manufactures and markets instruments and consumable products for blood diagnostics under its own direction. The company serves hospitals, clinics, laboratories and companies within blood diagnostics in both the human and veterinary areas. The group has an annual sale of a little over SEK 400 million and around 170 employees. Sales are made via distributors in over 100 countries and directly in Sweden and the USA. The company operates via subsidiary operating companies in Sweden, USA and China. Since 2011, Boule shares have been listed on the Nasdaq Stockholm.

The information was submitted for publication,through the agency of the contact person set out above, at 08:45 12 May, 2017